We are eager to initiate clinical development of our lead product candidate, PLN-74809, in early 2019 as a potential treatment option for patients with IPF.
IPF is a chronic and progressive fibrotic disease in which lung tissue becomes thickened, stiff and scarred, leading to increased difficulty in breathing and decreased quality of life. As lung fibrosis progresses, it becomes increasingly difficult for the lungs to transfer oxygen into the bloodstream— ultimately preventing vital organs from receiving the oxygen necessary to function properly. IPF currently affects approximately 140,000 people in the U.S.
If you are interested in learning more about this clinical trial, email us at firstname.lastname@example.org.